TTR V122I遗传变异与非洲或西班牙裔/拉丁裔人群心力衰竭的关联
基于两个学术医学中心生物样本库的横断面和病例对照分析,发现非洲裔或西班牙裔/拉丁裔人群中TTR V122I携带者心力衰竭患病率显著更高(调整OR约1.7-1.8),但携带合并心衰者中仅11%被临床诊断为hATTR-CM,中位诊断延迟3年。
要点
- TTR V122I携带者心衰风险显著增加,调整OR 1.7-1.8。
- 携带心衰者中仅11%被诊断为hATTR-CM,诊断率低。
- 症状出现至临床诊断中位时间3年,提示认识不足。
核心结论
- 在非洲或西班牙裔/拉丁裔人群中,TTR V122I遗传变异与心力衰竭显著相关。
- 携带心衰者中hATTR-CM临床诊断率低,中位诊断延迟3年。
研究设计与样本
- 横断面分析:Penn Medicine Biobank中2008-2017年入组的50岁及以上非洲裔个体3724人,使用1996-2017年电子健康记录。
- 病例对照研究:Mount Sinai BioMe Biobank中2007-2015年入组的非洲裔和西班牙裔/拉丁裔个体,包括心衰病例和对照,使用2007-2018年电子健康记录。
主要发现
- 92例携带TTR V122I的心衰患者中,10例(11%)被诊断为hATTR-CM,症状出现至临床诊断中位时间3年。
临床怎么用
- 对非洲裔或西班牙裔/拉丁裔心衰患者,应考虑TTR V122I基因检测以识别hATTR-CM。
- 提高对hATTR-CM的认识,缩短从症状出现到诊断的时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) due to the TTR V122I variant is an autosomal-dominant disorder that causes heart failure in elderly individuals of African ancestry. The clinical associations of carrying the variant, its effect in other African ancestry populations including Hispanic/Latino individuals, and the rates of achieving a clinical diagnosis in carriers are unknown. OBJECTIVE: To assess the association between the TTR V122I variant and heart failure and identify rates of hATTR-CM diagnosis among carriers with heart failure. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017. Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018. EXPOSURES: TTR V122I carrier status. MAIN OUTCOMES AND MEASURES: The primary outcome was prevalent heart failure. The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured. RESULTS: The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range, 57-71); 1755 (47%) were male, 2896 (78%) had a diagnosis of hypertension, and 753 (20%) had a history of myocardial infarction or coronary revascularization. There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure. The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range, 68-80), 2271 (38%) were male, 4709 (79%) had a diagnosis of hypertension, and 1008 (17%) had a history of myocardial infarction or coronary revascularization. There were 1376 cases of heart failure. TTR V122I was associated with higher rates of heart failure (cross-sectional cohort: n = 51/116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2-2.4], P = .006; case-control study: n = 36/1376 heart failure cases [2.6%], n = 82/4594 controls [1.8%], adjusted odds ratio, 1.8 [95% CI, 1.2-2.7], P = .008). Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clinical diagnosis was 3 years. CONCLUSIONS AND RELEVANCE: Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly associated with heart failure.
引用
- Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA. 2019. PMID: 31821430. doi:10.1001/jama.2019.17935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。